About Haystack Oncology
Haystack Oncology is a company based in Baltimore (United States) founded in 2021 was acquired by Quest Diagnostics in April 2023. Haystack Oncology has raised $67.02 million across 1 funding round from investors including ARE, Quest Diagnostics and Bruker. Haystack Oncology offers products and services including Haystack MRD. Haystack Oncology operates in a competitive market with competitors including Guardant Health, GRAIL, Natera, Foundation Medicine and ArcherDX, among others.
- Headquarter Baltimore, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Haystack Oncology, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$67.02 M (USD)
in 1 rounds
-
Latest Funding Round
$67.02 M (USD), Series A
Oct 17, 2022
-
Investors
ARE
& 4 more
-
Employee Count
Not available
-
Acquired by
Quest Diagnostics
(Apr 27, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Haystack Oncology
Haystack Oncology offers a comprehensive portfolio of products and services, including Haystack MRD.
Detects ultralow ctDNA levels for residual disease monitoring in cancer patients.
People of Haystack Oncology
Unlock access to complete
Unlock access to complete
Funding Insights of Haystack Oncology
Haystack Oncology has successfully raised a total of $67.02M through 1 strategic funding round. The most recent funding activity was a Series A round of $67.02 million completed in October 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Haystack Oncology
Haystack Oncology has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, Quest Diagnostics and Bruker.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital is provided to biomedical technology startups.
|
Locked | Locked | Locked | |
|
Diversified research instrument systems are manufactured and supplied.
|
Locked | Locked | Locked | |
|
Offers independent market intelligence for telecommunications, networking, and wireless markets.
|
Locked | Locked | Locked |
Investor details for Haystack Oncology
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Haystack Oncology
Investment portfolio details for Haystack Oncology
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Haystack Oncology
Detailed financials for Haystack Oncology
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Haystack Oncology Comparisons
Peer comparison for Haystack Oncology
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Haystack Oncology
Haystack Oncology operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, GRAIL, Natera, Foundation Medicine and ArcherDX, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Circulating tumor DNA is screened for early cancer detection.
|
|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Health risks are identified through online genetic and diagnostic testing.
|
Detailed competitors of Haystack Oncology
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Haystack Oncology
Complete news archive for Haystack Oncology
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Haystack Oncology
Haystack Oncology was founded in 2021 and raised its 1st funding round 1 year after it was founded.
Haystack Oncology is headquartered in Baltimore, United States. It is registered at Baltimore, Maryland, United States.
Dan Edelstein is the current CEO of Haystack Oncology.
Haystack Oncology is a funded company, having raised a total of $67.02M across 1 funding round to date.
Haystack Oncology was founded in 2021 and is based in Baltimore, United States. Operations focus on the oncology sector, where personalized diagnostic tests are developed using circulating tumor DNA detection technology. Minimal residual disease testing is optimized for recurrent or resistant cancers through tumor-informed liquid biopsies. These begin with tissue-based whole-exome sequencing to identify patient-specific mutations, supporting clinical decision-making in cancer care.
Haystack Oncology's top competitors include Guardant Health, GRAIL and Foundation Medicine.
Haystack Oncology offers Haystack MRD.
Haystack Oncology has 5 investors. Key investors include ARE, Quest Diagnostics, Bruker, Catalio Capital Management, and Exact Ventures.